Drugs / Uncultured, autologous, adipose-derived regenerative cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06705023 | Nov 2024 → Oct 2025 overdue | coronary artery disorder, left ventricular failure, myocardial infarction | Ralf Rothoerl | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-07-23 | InGeneron, Inc. | Results InGeneron Publishes Landmark Study Demonstrating Structural Tendon Regeneration with Autologous Cell Therapy System ingeneron.com ↗
The study, titled “ Regeneration of Biomechanically Functional Tendon Tissue Following Injection of Uncultured, Autologous, Adipose-Derived Regenerative Cells [UA-ADRCs] into Partial Achilles Tendon Defects in Rabbits “, provides robust evidence that InGeneron’s cell therapy restores functional tendon architecture, a key milestone in the company’s scientific narrative. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-07-23 | InGeneron, Inc. | InGeneron Publishes Landmark Study Demonstrating Structural Tendon Regeneration with Autologous Cell Therapy System ingeneron.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Uncultured, autologous, adipose-derived regenerative cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06705023 ↗ |
| Known as | UA-ADRCs | “Uncultured, autologous, adipose-derived regenerative cells (UA-ADRCs)” NCT06705023 ↗ |
| Route | Other | “Intracardial venous injection of fresh, uncultured, autologous, adipose-derived regenerative cells isolated from lipoaspirate at the point of care.” NCT06705023 ↗ |